Abstract Number: 1229 • 2017 ACR/ARHP Annual Meeting
Factors Affecting FRAX Score Calculation & Treatment in Practice
Background/Purpose: Osteoporosis-related fractures causes increased disability and morbidity and mortality. The FRAX algorithm quantifies the 10 year probability of a hip or major osteoporotic fracture.…Abstract Number: 2397 • 2017 ACR/ARHP Annual Meeting
Bilateral Femoral DXA Scan in Patients with Rheumatoid Arthritis
Background/Purpose: RA is in independent risk factor for osteoporosis and fractures. The diagnosis of osteoporosis is based on T-score at lumbar spine or hip and…Abstract Number: 2013 • 2014 ACR/ARHP Annual Meeting
Quality Appraisal of Educational Websites on Osteoporosis and Bone Health
Background/Purpose: Osteoporosis, like many other chronic diseases, can have better outcomes when informed patients get involved in self-management, resulting in better ourtcomes. Bone health education…Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…Abstract Number: 1162 • 2014 ACR/ARHP Annual Meeting
Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population
Background/Purpose: Osteoporosis is a widely prevalent but underrecognized condition. Oral bisphosphonates are considered first-line treatment of osteoporosis in men and women however long term use…Abstract Number: L18 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation of Bone Mineral Density Change in Women Receiving Depot Leuprolide Acetate during Cyclophosphamide Therapy for Severe Lupus Nephritis
Background/Purpose: Cohort studies demonstrate that 11-83% of female patients receiving cyclophosphamide (CYC) for treatment of severe manifestations of SLE develop premature ovarian failure (POF), dependent…